Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALDX Aldeyra Therapeutics

Post-Market Trading 12-23 19:25:50 EST

4.79

-0.09

-1.84%

盘后4.75

-0.04-0.84%

17:07 EST

High4.86	Low4.70	Vol219.37K
Open4.86	D1 Closing4.88	Amplitude3.28%
Mkt Cap285.24M	Tradable Cap207.21M	Total Shares59.55M
T/O1.04M	T/O Rate0.51%	Tradable Shares43.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":4.79,"timestamp":1734987600000,"preClose":4.88,"halted":0,"volume":219372,"hourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.79,"latestTime":"17:07 EST","volume":4200,"amount":19997.99928,"timestamp":1734991679103},"delay":0,"floatShares":43259662,"shares":59549598,"eps":-0.754272,"marketStatus":"Post-Market Trading","change":-0.09,"latestTime":"12-23 19:25:50 EST","open":4.86,"high":4.86,"low":4.7,"amount":1043714.500536,"amplitude":0.032787,"askPrice":5.4,"askSize":100,"bidPrice":4.3,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.754272,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1735002000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":4.88,"preHourTrading":{"tag":"盘前","latestPrice":4.88,"preClose":4.88,"latestTime":"09:25 EST","volume":3,"amount":14.64,"timestamp":1734963900080},"postHourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.79,"latestTime":"17:07 EST","volume":4200,"amount":19997.99928,"timestamp":1734991679103},"volumeRatio":0.480178,"impliedVol":1.8093,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/ALDX","defaultTab":"news","newsList":[{"id":"2493342762","title":"High Growth Tech Stocks To Watch In December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2493342762","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493342762?lang=en_us&edition=fundamental","pubTime":"2024-12-21 02:02","pubTimestamp":1734717771,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility.Top 10 High Growth Tech Companies In The United States. Take a closer look at Akebia Therapeutics' potential here in our health report.Examine Akebia Therapeutics' past performance report to understand how it has performed in the past.Aldeyra Therapeutics has demonstrated a robust commitment to innovation in the biotech sector, particu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IO2v6Az9Ftp5BwGxWk_U3A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8dd43bf33c3f09b3bd16e76b99877c31","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IO2v6Az9Ftp5BwGxWk_U3A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8dd43bf33c3f09b3bd16e76b99877c31"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-180251644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALDX","BK4139","INFN","AKBA"],"gpt_icon":0},{"id":"2491693830","title":"Analysts’ Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693830","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693830?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:50","pubTimestamp":1734353408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aldeyra Therapeutics (ALDX – Research Report) and Ke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-aldeyra-therapeutics-aldx-keros-therapeutics-kros?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-aldeyra-therapeutics-aldx-keros-therapeutics-kros?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4137","ALDX","HCSG","KROS"],"gpt_icon":0},{"id":"2490877071","title":"Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490877071","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490877071?lang=en_us&edition=fundamental","pubTime":"2024-12-09 23:05","pubTimestamp":1733756700,"startTime":"0","endTime":"0","summary":"Investors in Aldeyra Therapeutics, Inc. ALDX need to pay close attention to the stock based on moves in the options market lately. That is because the March 3, 2025 $2.50 Call had some of the highest implied volatility of all equity options today.Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.Clearly, options traders are pricing in a big move for Aldeyra Therapeutics shares, but what is the fundamental picture for the company?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/options-market-predicting-spike-aldeyra-150500800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2490723668","title":"Positive Outlook for Aldeyra Therapeutics: Buy Rating Backed by Promising Reproxalap Prospects and Strategic Partnership with AbbVie","url":"https://stock-news.laohu8.com/highlight/detail?id=2490723668","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490723668?lang=en_us&edition=fundamental","pubTime":"2024-12-09 19:32","pubTimestamp":1733743921,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics (ALDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-aldeyra-therapeutics-buy-rating-backed-by-promising-reproxalap-prospects-and-strategic-partnership-with-abbvie?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-aldeyra-therapeutics-buy-rating-backed-by-promising-reproxalap-prospects-and-strategic-partnership-with-abbvie?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","ABBV"],"gpt_icon":0},{"id":"2488977011","title":"Oppenheimer pharmaceuticals analysts hold analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2488977011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488977011?lang=en_us&edition=fundamental","pubTime":"2024-12-04 06:25","pubTimestamp":1733264708,"startTime":"0","endTime":"0","summary":"Pharmaceuticals Analysts discuss Aldeyra Therapeutics’ (ALDX) Reproxalap and its commercial potential in Dry Eye Disease on an Analyst/Industry con...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-pharmaceuticals-analysts-hold-analyst-industry-conference-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-pharmaceuticals-analysts-hold-analyst-industry-conference-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","BK4127","OPY","BK4139"],"gpt_icon":0},{"id":"2488570954","title":"Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2488570954","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488570954?lang=en_us&edition=fundamental","pubTime":"2024-12-02 20:00","pubTimestamp":1733140800,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., December 02, 2024----Aldeyra Therapeutics, Inc.  , a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at the Citi 2024 Global Healthcare Conference. The conference is being conducted in Miami, Florida December 2-5, 2024.About AldeyraAldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP  modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aldeyra-therapeutics-participate-citi-2024-120000904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALDX","HCSG","BK4137","BK4139"],"gpt_icon":0},{"id":"2484920578","title":"ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap","url":"https://stock-news.laohu8.com/highlight/detail?id=2484920578","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484920578?lang=en_us&edition=fundamental","pubTime":"2024-11-19 23:00","pubTimestamp":1732028400,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics, Inc. ALDX announced that the FDA has accepted its resubmitted new drug application  for reproxalap, a first-in-class investigational RASP modulator, for the treatment of the signs and symptoms of dry eye disease.With the FDA accepting the resubmitted NDA for review, a decision from the regulatory body is expected on April 2, 2025.Simultaneously, Aldeyra announced that it has expanded its existing option agreement with AbbVie ABBV.Shares of Aldeyra were up 11.6% on Nov. 18 following the announcement of the news. The stock has rallied 33.9% so far this year against the industry’s decline of 6%.If ABBV chooses to exercise the option, ALDX will be eligible to receive an upfront payment of $100 million less option fees of $6 million, which was previously paid. Additionally, Aldeyra is eligible to receive up to $300 million in regulatory and commercial milestone payments from AbbVie, including a $100 million","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4qYAeIby_0fxQYGokmloZw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4qYAeIby_0fxQYGokmloZw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aldx-fda-accepts-resubmitted-nda-150000461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRL","LU2089984988.USD","LU0198837287.USD","LU1093756168.USD","SG9999011175.SGD","LU2133065610.SGD","IE00B3PB1722.GBP","BK4588","SG9999015952.SGD","LU2112291526.USD","BK4121","LU0114720955.EUR","LU0211328371.USD","IE0002141913.USD","LU0943347566.SGD","LU1003077747.HKD","LU0985320562.USD","LU0689472784.USD","LU0708994859.HKD","LU0795875169.SGD","LU0820561818.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","LU0203345920.USD","LU2468319806.SGD","LU0128525929.USD","IE00B42XCP33.USD","BK4196","IE00BSNM7G36.USD","BK4581","IMCR","LU0965509010.AUD","LU1585245621.USD","LU1718418525.SGD","LU1934455863.HKD","LU2023251221.USD","LU0882574055.USD","LU1989772840.SGD","LU0545039389.USD","SG9999015986.USD","LU1057294990.SGD","IE00BGHQF631.EUR","ABBV","LU0912757837.SGD","LU2237443895.HKD","LU0965508806.USD","LU0122379950.USD","LU1267930490.SGD","ALDX","CSTL"],"gpt_icon":0},{"id":"2484983349","title":"Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2484983349","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484983349?lang=en_us&edition=fundamental","pubTime":"2024-11-19 04:05","pubTimestamp":1731960300,"startTime":"0","endTime":"0","summary":"Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review.The stock rose 11% to $4.67 in afternoon trading Monday. Shares, despite falling 12% in the last three months, are up 35% this year.The Lexington, Mass., biotechnology company said its first-in-class drug candidate, topical ocular reproxalap, can treat the signs and symptoms of dry eye disease.With the treatment accepted for review Aldeyra also expanded its exclusive option agreement with AbbVie. The agreement, which the companies entered into in October 2023, provides AbbVie with the option to obtain a co-exclusive license to develop, manufacture and commercialize reproxalap in the U.S., Aldeyra said.Under the agreement, AbbVie would make an upfront payment of $100 million to Aldeyra, minus $6 million in previously paid option fees. Aldeyra would also be eligible to receive up to $300 million in regulatory ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2484396945","title":"Aldeyra announces FDA acceptance of resubmitted reproxalap application","url":"https://stock-news.laohu8.com/highlight/detail?id=2484396945","media":"seekingalpha","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484396945?lang=en_us&edition=fundamental","pubTime":"2024-11-19 01:09","pubTimestamp":1731949756,"startTime":"0","endTime":"0","summary":"hapabapa Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular reproxalap for the treatment of dry eye disease and an expansion of its option agreement with AbbVie (NYSE:ABBV). The biotech company said the FDA has assigned","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4303372-aldeyra-announces-fda-acceptance-of-resubmitted-reproxalap-application","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["LU0170899867.USD","SQQQ","LU2237443895.HKD","PSQ","ALDX","IE00BVYPNV92.GBP","SG9999011175.SGD","BK4533","QLD","LU0965508806.USD","LU1983299246.USD","MNQmain","LU0456855351.SGD","LU0820561818.USD","QID","LU1267930573.SGD","LU0965509010.AUD",".IXIC","IE00BDGV0183.EUR","LU1551013425.SGD","LU0417517546.SGD","LU1244550577.SGD","LU0965509101.SGD","SG9999001440.SGD","LU0708994859.HKD","BK4534","SG9999015952.SGD","LU0861579265.USD","LU1732799900.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU0128525929.USD","LU0965509283.SGD","LU1267930490.SGD","LU2237443465.HKD","LU0114720955.EUR","ABBV","LU0689472784.USD","NQmain","SG9999015978.USD","LU0310800379.SGD","LU1244550494.USD","IE00B42XCP33.USD","LU1244550221.USD","LU0234570918.USD","TQQQ","LU1496350502.SGD","LU1291159041.SGD","BK4139"],"gpt_icon":0},{"id":"2484962400","title":"Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2484962400","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484962400?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:01","pubTimestamp":1731934863,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics  said Monday that the US Food and Drug Administration has accepted its resubmitted new drug application for its topical ocular reproxalab, a treatment for dry eye disease.The company said the FDA has assigned a Prescription Drug User Fee Act date of April 2.Aldeyra has also expanded its option agreement with AbbVie , which was entered into in October and could give the latter a co-exclusive license to develop, manufacture and commercialize the drug candidate in the US.If AbbVie exercises the option, Aldeyra will receive a $100 million upfront payment, plus up to $300 million in milestone payments.The company said it would share profits from the commercialization of reproxalap in the US under a split of 60% for AbbVie and 40% for Aldeyra.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","LU1732800096.USD","BK4566","LU1496350502.SGD","LU0198837287.USD","LU0256863811.USD","LU0661504455.SGD","LU1061106388.HKD","IE00BVYPNV92.GBP","LU2133065610.SGD","LU2347655156.SGD","LU0029864427.USD","BK4550","SG9999015952.SGD","IE00BVYPNW00.USD","LU0256863902.USD","LU1551013342.USD","LU0158827948.USD","LU0114720955.EUR","LU1839511570.USD","LU0310800379.SGD","LU0310799852.SGD","BK4585","LU1003077747.HKD","LU0985320562.USD","LU1430594728.SGD","LU1551013425.SGD","LU0795875169.SGD","LU1732799900.SGD","LU2087621335.USD","IE00BJT1NW94.SGD","LU1989772923.USD","LU2237443622.USD","SG9999001440.SGD","BK4581","LU0234572021.USD","LU0965509010.AUD","LU1093756325.SGD","LU1496350171.SGD","LU0861579265.USD","LU2023251221.USD","LU1244550494.USD","LU1244550577.SGD","LU2237443549.SGD","ABBV","LU0203347892.USD","LU1037948897.HKD","LU0965508806.USD","ALDX","LU0234570918.USD"],"gpt_icon":0},{"id":"2484291576","title":"Aldeyra says FDA accepts reproxalap NDA,  AbbVie deal expanded to $100M","url":"https://stock-news.laohu8.com/highlight/detail?id=2484291576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484291576?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:16","pubTimestamp":1731932199,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics (ALDX) announced that the U.S. Food and Drug Administration or FDA has accepted for review the resubmitted New Drug Applicatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aldeyra-says-fda-accepts-reproxalap-nda-abbvie-deal-expanded-to-100m?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aldeyra-says-fda-accepts-reproxalap-nda-abbvie-deal-expanded-to-100m?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443465.HKD","BK4566","LU0882574055.USD","LU1093756168.USD","LU0456855351.SGD","IE00BVYPNW00.USD","LU0256863902.USD","LU0170899867.USD","LU1551013342.USD","LU0545039389.USD","LU1430594728.SGD","LU1037948897.HKD","LU0912757837.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0738911758.USD","LU1267930490.SGD","BK4585","SG9999015986.USD","ALDX","LU1244550577.SGD","LU2347655156.SGD","IE0002141913.USD","ABBV","LU0689472784.USD","LU0553294199.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0965509010.AUD","LU1718418525.SGD","LU2237443549.SGD","LU0820561909.HKD","LU2089984988.USD","LU1934455194.USD","LU0211328371.USD","LU0795875086.SGD","BK4533","LU1934455277.USD","LU2087621335.USD","LU0029864427.USD","LU1037948541.HKD","IE00BDGV0183.EUR","LU0128525929.USD","LU0211327993.USD","LU0661504455.SGD","LU1839511570.USD","LU0234570918.USD","LU1496350171.SGD","LU1732800096.USD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2484626429","title":"Aldeyra Therapeutics Inc: Abbvie Has Also Independently Initiated Certain Pre-Commercial Planning Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2484626429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484626429?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABPZKYQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0211327993.USD","LU2089284900.SGD","LU0965509283.SGD","LU0256863902.USD","LU0198837287.USD","SG9999015986.USD","LU2087621335.USD","IE00BVYPNW00.USD","LU0158827948.USD","LU1551013425.SGD","LU0211328371.USD","LU0170899867.USD","LU1003077747.HKD","LU1093756168.USD","ABBV","LU0795875169.SGD","ALDX","IE00B42XCP33.USD","LU0965508806.USD","LU0795875086.SGD","LU0661504455.SGD","SG9999015952.SGD","SG9999001440.SGD","LU0949170772.SGD","IE00BFTCPJ56.SGD","LU2347655156.SGD","LU2133065610.SGD","IE0002141913.USD","LU0310799852.SGD","IE00BDGV0183.EUR","IE0009355771.USD","LU2089283258.USD","LU1430594728.SGD","BK4585","LU1244550221.USD","LU0310800379.SGD","LU2112291526.USD","LU0122379950.USD","LU0965509010.AUD","LU2237443382.USD","LU1732800096.USD","IE00BGHQF631.EUR","LU0203347892.USD","LU0545039389.USD","LU0708994859.HKD","LU1496350171.SGD","SG9999011175.SGD","LU0234570918.USD","LU0943347566.SGD","LU0256863811.USD"],"gpt_icon":0},{"id":"2484462642","title":"Aldeyra Therapeutics:  Will Initiate Certain Pre-Commercial Activities, 60% of Which Will Be Paid by Abbvie, 40% by Co IF Option Is Exercised","url":"https://stock-news.laohu8.com/highlight/detail?id=2484462642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484462642?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABPZKYQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0211327993.USD","LU2112291526.USD","SG9999015952.SGD","LU1551013425.SGD","SG9999011175.SGD","LU0965509283.SGD","LU0965508806.USD","LU0949170772.SGD","LU1496350171.SGD","IE00BFTCPJ56.SGD","LU0234570918.USD","ALDX","LU0661504455.SGD","LU0795875169.SGD","LU2347655156.SGD","SG9999015986.USD","IE00BGHQF631.EUR","LU0122379950.USD","LU0256863902.USD","LU0211328371.USD","LU0965509010.AUD","LU2087621335.USD","IE00B42XCP33.USD","LU0198837287.USD","LU1003077747.HKD","LU1244550221.USD","LU2133065610.SGD","LU1732800096.USD","LU2237443382.USD","LU0170899867.USD","IE00BVYPNW00.USD","LU0943347566.SGD","LU0708994859.HKD","LU0310799852.SGD","LU2089283258.USD","ABBV","LU2089284900.SGD","LU0545039389.USD","LU0310800379.SGD","IE00BDGV0183.EUR","BK4585","IE0009355771.USD","IE0002141913.USD","LU0158827948.USD","LU0795875086.SGD","LU1093756168.USD","SG9999001440.SGD","LU1430594728.SGD","LU0256863811.USD","LU0203347892.USD"],"gpt_icon":0},{"id":"2484421626","title":"Aldeyra: Abbvie Agreed to Amend Expiration of Option to 10 Business Days From Date of FDA Approval, IF Any, of Reproxalap for Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484421626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484421626?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABPZKYQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0256863811.USD","LU1003077747.HKD","SG9999015986.USD","LU0158827948.USD","LU1551013425.SGD","LU0708994859.HKD","LU0661504455.SGD","LU0211328371.USD","IE00BGHQF631.EUR","IE0002141913.USD","SG9999001440.SGD","LU1496350171.SGD","LU2087621335.USD","LU2089284900.SGD","IE00B42XCP33.USD","LU0545039389.USD","LU0122379950.USD","SG9999015952.SGD","ALDX","LU0256863902.USD","LU0170899867.USD","LU1093756168.USD","IE00BDGV0183.EUR","LU0965508806.USD","LU0795875169.SGD","IE00BFTCPJ56.SGD","IE00BVYPNW00.USD","LU0949170772.SGD","ABBV","LU0310799852.SGD","LU0310800379.SGD","LU2112291526.USD","LU0965509283.SGD","LU0965509010.AUD","BK4585","LU2237443382.USD","LU2089283258.USD","LU0198837287.USD","LU0211327993.USD","LU0234570918.USD","IE0009355771.USD","LU0203347892.USD","LU2347655156.SGD","LU1244550221.USD","LU0943347566.SGD","LU0795875086.SGD","LU2133065610.SGD","LU1430594728.SGD","LU1732800096.USD","SG9999011175.SGD"],"gpt_icon":0},{"id":"2484362684","title":"Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands Abbvie Option Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2484362684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484362684?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABPZKYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2484362666","title":"Aldeyra Therapeutics Inc - Pdufa Date Set for April 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2484362666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484362666?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUABPZKYQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2484627659","title":"Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2484627659","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484627659?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., November 18, 2024----Aldeyra Therapeutics, Inc.   today announced that the U.S. Food and Drug Administration  has accepted for review the resubmitted New Drug Application  for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act  date of April 2, 2025. In conjunction with the acceptance of the NDA for review, Aldeyra announced the expansion of its exclusive option agreement with AbbVie Inc. .Reproxalap is an investigational new drug candidate in development for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology. Reproxalap is a first-in-class small-molecule modulator of RASP, which are elevated in ocular and systemic inflammatory diseases. The mechanism of action of reproxalap has been supported by the demonstration of statistically significant and clinically relevant activit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aldeyra-therapeutics-announces-fda-acceptance-120000642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2112291526.USD","LU1551013425.SGD","SG9999015978.USD","LU0965509283.SGD","LU0965508806.USD","LU1291159041.SGD","LU1718418525.SGD","IE00BFTCPJ56.SGD","ALDX","LU0985320562.USD","LU0795875169.SGD","SG9999015986.USD","IE00B4R5TH58.HKD","IE00BSNM7G36.USD","LU2237443549.SGD","LU0256863902.USD","LU2089984988.USD","LU0820561909.HKD","LU1983299246.USD","LU2237443895.HKD","LU0198837287.USD","LU1003077747.HKD","LU1244550221.USD","LU1551013342.USD","LU2133065610.SGD","LU1732800096.USD","LU2237443382.USD","LU0170899867.USD","LU0689472784.USD","IE00BVYPNW00.USD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU2089283258.USD","ABBV","BK4550","LU0820561818.USD","LU2089284900.SGD","LU1037948897.HKD","LU0545039389.USD","BK4588","IE00BDGV0183.EUR","LU0417517546.SGD","LU0203345920.USD","IE0002141913.USD","LU0795875086.SGD","IE00BJJMRZ35.SGD","BK4534","LU0203347892.USD","LU1732799900.SGD","LU1244550494.USD"],"gpt_icon":0},{"id":"2483080516","title":"Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483080516","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483080516?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:40","pubTimestamp":1731422413,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BellRing Brands  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.BellRing Brands is one of 1024 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BellRing Brands is currently sporting a Zacks Rank of #2 .Another stock in the Medical sector, Aldeyra Therapeutics, Inc. , has outperformed the sector so far this year. The stock's year-","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gUf3JPAiwp3PVjuDKftvaA--~B/aD04NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gUf3JPAiwp3PVjuDKftvaA--~B/aD04NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bellring-brands-brbr-outperforming-other-144013421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BRBR","ALDX"],"gpt_icon":1},{"id":"2479702646","title":"Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2479702646","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479702646?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372400,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., October 31, 2024----Aldeyra Therapeutics, Inc.  , a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News  New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024.Dr. Stryjewski will provide an overview of the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa. The session will run from 3:30 – 5:30 p.m. ET on Friday, November 8, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aldeyra-therapeutics-selected-present-disruptive-110000365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALDX","BK4139","OSN"],"gpt_icon":0},{"id":"2479748828","title":"Aldeyra Therapeutics Inc    expected to post a loss of 25 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2479748828","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479748828?lang=en_us&edition=fundamental","pubTime":"2024-10-31 11:30","pubTimestamp":1730345400,"startTime":"0","endTime":"0","summary":"* Aldeyra Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on November 1 (estimated) for the period ending September 30 2024   *    * LSEG's mean analys","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Aldeyra Therapeutics Inc    expected to post a loss of 25 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aldeyra.com","stockEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0252},{"period":"3month","weight":-0.1715},{"period":"6month","weight":0.4023},{"period":"1year","weight":0.4567},{"period":"ytd","weight":0.3903}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.077344},{"month":2,"riseRate":0.6,"avgChangeRate":0.000014},{"month":3,"riseRate":0.4,"avgChangeRate":-0.001859},{"month":4,"riseRate":0.5,"avgChangeRate":0.045254},{"month":5,"riseRate":0.4,"avgChangeRate":0.032473},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.035553},{"month":7,"riseRate":0.545455,"avgChangeRate":0.029811},{"month":8,"riseRate":0.454545,"avgChangeRate":0.039547},{"month":9,"riseRate":0.545455,"avgChangeRate":0.194872},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.097688},{"month":11,"riseRate":0.636364,"avgChangeRate":0.079434},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.031878}],"exchange":"NASDAQ","name":"Aldeyra Therapeutics","nameEN":"Aldeyra Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aldeyra Therapeutics,ALDX,Aldeyra Therapeutics股票,Aldeyra Therapeutics股票老虎,Aldeyra Therapeutics股票老虎国际,Aldeyra Therapeutics行情,Aldeyra Therapeutics股票行情,Aldeyra Therapeutics股价,Aldeyra Therapeutics股市,Aldeyra Therapeutics股票价格,Aldeyra Therapeutics股票交易,Aldeyra Therapeutics股票购买,Aldeyra Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction